41 in-depth guides in this cluster
Funding a MedTech startup is not the same as funding SaaS. The cost of regulation, the time to revenue, and the investor expectations all differ. Here is the complete guide.
MedTech startups need 3-10x more capital than SaaS to reach revenue. The difference is not technical complexity — it is the 18-24 month regulatory path. Here is the math.
Raising pre-seed and seed for a MedTech startup is harder than SaaS because investors want evidence of the regulatory path. Here is what they actually want to see.
Series A in MedTech needs more than PMF. Investors want a regulatory milestone, clinical evidence plan, and path to revenue. Here is what to show.
European MedTech VC has matured but still lags US deal sizes. Here is the 2026 investor landscape and what MedTech founders should expect at each round.
Where MedTech angel investors concentrate, what they fund, and why regulatory readiness is the filter that decides who writes the first check.
Non-dilutive funding can carry a MedTech startup through the regulatory valley without giving up equity. Here is the landscape across Europe in 2026.
Horizon Europe, EIC Accelerator, EIT Health — the EU funding stack for MedTech is complex. Here is the overview at general framing.
Austria has one of Europe's strongest MedTech funding ecosystems. Here is how AWS, FFG, and regional programs work for startups — with the honest caveats on current terms.
EXIST, BMBF, and state-level funding for German MedTech startups — eligibility, regulatory milestones tied to disbursement, and what to apply for when.
Innosuisse, cantonal programmes, and the third-country reality of Switzerland under MDR — how Swiss MedTech startups fund the extra regulatory burden.
The EIC Accelerator is the largest non-dilutive grant programme for European MedTech. Here is how to write a winning application at general framing.
Every MedTech pitch deck needs a regulatory slide. Here is what MedTech investors actually want to see on it — and what kills the round.
What MedTech investors check in regulatory and QMS due diligence: red flags that kill rounds, the evidence pack to assemble, who gets interrogated.
When strategic investors and corporate VCs make sense for MedTech startups, what they bring beyond money, and the alignment risks to weigh first.
Legal ways to generate revenue before CE mark: services, custom-made devices, R&D contracts, and investigational use — with MDR citations.
Crowdfunding medical devices legally: MDR Article 7 promotional traps, Article 5 placement rules, pre-orders, and equity crowdfunding alternatives.
A MedTech startup budget must allocate for regulatory work from day one. Here is the line-by-line budget template and the common traps founders fall into.
The real cost of CE marking a medical device in 2026, broken down by category and class. Useful for investor pitches and founder sanity.
MedTech burn rate is determined by regulatory milestones, not feature releases. Here is how to manage burn rate so you reach CE marking without a gap round.
How to build a defensible financial model for a MedTech startup when MDR timelines, notified body queues, and audit cycles drive every assumption.
A startup guide to reimbursement strategy for medical devices in Europe: why CE mark is not enough, how HTA works, and how to sequence markets.
Health insurance reimbursement in Europe is country-specific, slow, and the gating factor for revenue. Here is the founder's primer.
Germany is Europe's largest medical device market. Here is the GKV, NUB, and DRG reimbursement framework for MedTech startups at general framing.
How French reimbursement works for medical devices: LPPR listing, CNEDIMTS evaluation, evidence demands, timelines, and common rejection reasons.
UK reimbursement medical devices NHS NICE: how NHS procurement, NICE appraisal and UKCA marking fit together, and how EU startups should sequence entry.
How Austrian social insurance, hospital budgets, and the LKF system reimburse medical devices — and what MedTech founders need to prepare.
What health economic evaluation actually is for MedTech startups — cost-effectiveness, budget impact, QALYs, and when to commission a study.
Health Technology Assessment bodies decide whether a device deserves public coverage. Here is how to prepare the evidence submission at general framing.
How coverage with evidence development (CED) lets MedTech startups get reimbursed while generating the clinical data payers demand.
Value-based pricing medical devices: how outcome-based contracting works, evidence you need, risks, and how MDR PMS becomes your data backbone.
Reimbursement digital health Europe beyond DiGA: Germany, France PECAN, Belgium m-Health. Country-by-country evidence, MDR overlap, dual-pathway strategy.
Reimbursement strategy regulatory strategy MedTech: plan both together. Evidence stack design, Article 61, classification and HTA, startup playbook.
MedTech exits look different from SaaS exits. Here is the M&A, IPO, and partnership reality for MedTech startups in Europe.
How MedTech acquirers diligence regulatory assets under MDR — CE certificate transferability, QMS maturity, CER currency, and PMS continuity.
How to license MedTech technology to established companies under MDR — who becomes the manufacturer, royalty structures, IP carve-outs, and regulatory hand-over.
MedTech valuations are anchored to regulatory milestones more than to revenue. Here is how each milestone moves the value.
Cash flow management for MedTech startups — timing regulatory costs against revenue, managing the cash trough, and surviving the MDR Article 52 assessment cycle.
Extend runway in MedTech without breaking MDR. What costs you can defer, what must stay, and how to stretch capital without losing compliance.
The MedTech startup funding checklist for 2027. Regulatory deliverables mapped to each round from pre-seed to Series A, with investor red flags.
Treat regulatory costs as COGS, not one-off CapEx. Why MDR Article 10 obligations belong in MedTech unit economics and how to model them honestly.